Indo Us Biotech Limited

NSE: INDOUS · Unclassified

₹65.34-1.85%06 Nov 2026

Ask the data

Instant answers about Indo Us Biotech Limited — computed from its filings, no language model

Market cap₹131 cr

Current price₹65.34

High / Low₹151 / ₹60

P/E30.2

P/B1.43

Book value₹45.8

ROE4.7%

ROCE5.8%

Debt / equity0.48

Dividend yield—

EPS (TTM)₹2.16

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY25	FY26
Revenue	103.8	110.4
EBITDA	18.9	17.0
Operating margin	18.2%	15.4%
Interest	1.5	2.2
Depreciation	1.1	0.9
Profit before tax	16.5	13.9
Tax	0.3	0.8
Net profit	16.3	13.1
EPS ₹	8.12	6.54
Operating cash flow	-1.4	-16.1
Capex	0.0	-2.4
Dividend paid	0.5	0.0
Total assets	97.8	133.1
Equity	78.5	92.5

Quarterly performance

last 12 quarters · ₹ crore

showing latest 8 of 12 periods

	JUN '23†	DEC '23†	JUN '24†	SEP '24	DEC '24†	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	19.1	22.1	24.7	22.2	23.6	33.4	30.8	30.9	22.8	26.0	33.0	15.1
Operating profit	3.0	4.2	3.7	5.1	5.5	4.6	5.5	4.2	4.2	3.2	4.0	-2.6
Operating margin	15.6%	19.2%	14.9%	23.1%	23.5%	13.7%	17.8%	13.5%	18.2%	12.4%	12.0%	-17.3%
Other income	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1
Interest	0.4	0.4	0.3	0.5	0.4	0.3	0.5	0.4	0.8	0.6	0.7	0.8
Depreciation	0.2	0.2	0.2	0.2	0.2	0.6	0.2	0.2	0.2	0.3	0.3	0.3
Profit before tax	2.5	3.8	3.2	4.5	5.0	3.9	4.8	3.6	3.2	2.4	3.1	-3.6
Tax	0.1	0.1	0.0	0.1	-0.0	0.2	0.1	0.1	0.2	0.4	0.0	0.0
Net profit	2.4	3.7	3.2	4.4	5.0	3.7	4.7	3.5	3.0	2.0	3.0	-3.7
EPS ₹	4.74	1.84	1.58	2.16	2.52	1.86	2.35	1.72	1.49	0.98	1.51	-1.83
Revenue YoY	—	—	29.2%	—	6.6%	—	24.5%	39.2%	-3.2%	-22.0%	7.2%	-51.2%
Profit YoY	—	—	33.8%	—	36.9%	—	48.3%	-20.9%	-40.6%	-46.5%	-35.3%	-206.4%

Returns & margins

trailing-twelve-month, per quarter

	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	20.7%	22.7%	19.5%	17.1%	14.2%	12.4%	4.7%
ROCE	19.3%	21.2%	16.4%	15.2%	12.5%	11.4%	5.8%
Net margin	15.7%	16.2%	14.2%	12.6%	11.9%	10.2%	4.5%
EBITDA margin	18.2%	18.8%	16.7%	15.6%	15.4%	13.8%	9.0%
Debt / equity	0.19	0.19	0.32	0.32	0.40	0.40	0.48
Interest coverage	12.10	12.29	12.44	9.12	7.21	5.81	2.70
Asset turnover	1.06	1.12	1.01	1.01	0.83	0.85	0.69

Balance sheet

equity vs borrowings over time · ₹ crore

	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	20.1	20.1	20.1	20.1	20.1
Other equity / reserves	50.2	58.5	66.6	72.5	71.8
Total equity	70.2	78.5	86.7	92.5	91.9
Borrowings	15.1	14.8	27.6	37.0	44.2
Current liabilities	13.3	16.3	29.1	39.5	39.9
Non-current liabilities	4.3	3.0	1.5	1.0	8.5
Total assets	87.8	97.8	117.2	133.1	140.3
Property, plant & equipment	6.4	10.2	9.5	11.2	11.2
Capital work-in-progress	4.2	—	0.0	0.5	1.0
Investments	0.0	0.0	0.0	0.0	0.0
Inventories	42.9	70.7	60.9	100.0	86.0
Receivables	23.7	15.0	33.4	13.8	36.3
Cash & equivalents	1.0	0.2	0.6	6.1	2.3

Cash flow

annual · ₹ crore · line = free cash flow

	FY25	FY26
Cash from operations	-1.4	-16.1
Cash from investing	-0.8	3.3
Cash from financing	-1.5	24.4
Capex	0.0	-2.4
Free cash flow	-1.4	-13.7
Dividends paid	0.5	0.0

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹11.2 cr8%

CWIP

₹1.0 cr1%

Inventories

₹86.0 cr61%

Receivables

₹36.3 cr26%

Cash & equivalents

₹2.3 cr2%

Other assets

₹3.5 cr2%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Indo Us Biotech Limited	131	65.34	30.2	1.43	4.7%

StoxGud checklist: Bearish setup · 2/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-12.8%

6 months-42.0%

1 year-54.1%

3Y CAGR—

5Y CAGR—

10Y CAGR—

50-day avg₹75.02

200-day avg₹96.35

RSI (14)45

FAQs

What is the share price of Indo Us Biotech Limited?

Indo Us Biotech Limited (INDOUS) closed at ₹65.34 on NSE on 06 Nov 2026.

What is the market cap of Indo Us Biotech Limited?

₹131 crore at the latest close.

What is the P/E ratio of Indo Us Biotech Limited?

30.2, on trailing-twelve-month earnings from its filings.

How fast is Indo Us Biotech Limited growing?

Indo Us Biotech Limited: Latest-quarter revenue is down 51.2% year on year, profit down 206.4%.

How profitable is Indo Us Biotech Limited?

On a trailing-twelve-month basis return on equity is 4.7%, return on capital employed 5.8%, operating margin 9.0%, net margin 4.5%.

How much debt does Indo Us Biotech Limited have?

Indo Us Biotech Limited is lightly geared: debt to equity is 0.48 with borrowings of ₹44 cr against cash of ₹2 cr (balance sheet of 2026-09-30). Operating profit covers interest 2.7 times.

Financials parsed from Indo Us Biotech Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from JUN '23, annual from FY25, balance sheet from Sep '24. * = derived (full year or half year minus earlier quarters). † = the company's standalone results as published on BSE, used for quarters before SEP '24 and quarters missing from the NSE filings (full years marked † are summed from them); cross-checked against the NSE filings where both exist. Information only, not investment advice.